NEW YORK, Oct. 11, 2021 /PRNewswire/ — WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Adamas Pharmaceuticals, Inc. («Adamas» or the «Company») (NASDAQ: ADMS) in connection with the proposed acquisition of the Company by Supernus Pharmaceuticals, Inc. («Supernus») (NASDAQ: SUPN), via a tender offer. Under the terms of the merger agreement, the Company’s shareholders will receive $8.10 per share in cash payable at closing, plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash, payable upon achieving certain net sales thresholds of the Company’s lead product, GOCOVRI, for each share of Adamas common stock that they hold.
If you own Adamas shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:
Or please contact:
Joshua Rubin, Esq.
305 Broadway, 7th Floor
New York, NY 10007
WeissLaw LLP is investigating whether (i) Adamas’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $8.10 per-share offer price adequately compensates Adamas’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed. Notably, the merger consideration is below the $9.00 median price targets set by analysts following the Company and at least one analyst set a price target for the Company of $14 per share, $5.90 above the per-share merger consideration.
WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at email@example.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-adamas-pharmaceuticals-inc-301397431.html
SOURCE WeissLaw LLP